Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
What chemotherapy regimen would you use for a woman with pre-existing neuropathy causing imbalance, who now has a T1N0 ER+ and Her2+ breast cancer?
Answer from: Medical Oncologist at Community Practice
If the tumor is T1c, you can consider AC x4. Afterwards, single-agent Herceptin could be considered.
Sign in or Register to read more
17705
Related Questions
Does delay to the time of lumpectomy impact your decision to omit radiation?
What is the preferred duration of adjuvant aromatase inhibitor therapy in patients with triple positive breast cancer?
Would you discontinue or dose-reduce tamoxifen in a patient who developed hepatic steatosis?
When do you start adjuvant radiation with areas of delayed wound healing after reduction mammoplasty?
Would you offer adjuvant endocrine therapy to a patient with a history of ER-positive DCIS, s/p bilateral mastectomy, now with chest wall recurrence of DCIS four years later?
Would you offer adjuvant endocrine therapy for a postmenopausal female with stage III triple positive multicentric breast cancer (DCIS and invasive ductal carcinoma) s/p neoadjuvant TCHP followed by bilateral mastectomy with no residual disease?
What are your top takeaways in Breast Cancer from ESMO 2024?
Would you offer adjuvant AC + pembrolizumab for a triple negative breast cancer patient whose tumor progressed on carboplatin + paclitaxel + pembrolizumab on KEYNOTE-522 and required urgent surgery (ypT3 ypN0)?
How do you approach the RxPonder data in premenopausal women with ER/PR+, HER2 negative, pN1, many of whom now qualify for CDK 4/6 inhibitors in adjuvant setting besides endocrine therapy (+/- OFS) if the RS 0-13 and 14-25?
How do the results of INSEMA and SOUND impact the decision of omitting SLND in young women with breast cancer and offering adjuvant RT to patients who would otherwise be candidates for omission?